Skip to main content
MEDS
NASDAQ Trade & Services

Stockholders Clear Blank Check Preferred Stock, Opening Door to 95% Dilution

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Consumer
Sentiment info
Negative
Importance info
8
Price
$0.991
Mkt Cap
$2.926M
52W Low
$0.823
52W High
$86
52W Position info
20% above low
Off High info
99% below high
Rel. Volume info
30× avg
Market data snapshot near publication time

MEDS sits 20% above its 52-week low of $0.823 on elevated volume (30× avg).

Summary

Stockholders approved a blank check preferred stock authorization that enables conversion of $21.1M in convertible notes into Series A Preferred Stock with a variable conversion price — potentially diluting existing shareholders by up to 95%.


Key Events · Financing and Capital Events · MEDS

  • Blank Check Preferred Stock Authorized

    Stockholders holding 50.2% of outstanding shares approved an amendment authorizing 1,000,000 shares of blank check preferred stock via written consent dated August 25, 2026.

  • Series A Preferred Stock Terms Revealed

    The Series A Preferred Stock carries a $1,000 stated value, 10% annual dividend accrual after six months, and a conversion price reset to the lesser of $50.00 or market price with a floor dropping to 20% of the closing price on the Mandatory Conversion Date.

  • Up to 95.2% Dilution to Existing Shareholders

    Company dilution tables show that at a $0.50 conversion price, existing common stockholders would face approximately 95.2% dilution from conversion of the May 2026 Notes and exercise of PIPE and PA Warrants.

  • Death-Spiral Financing Structure

    The variable conversion price means a declining stock price triggers issuance of more shares, which can further depress the stock price and encourage short selling — a toxic feedback loop.


Analysis · MEDS · Trade & Services

A written consent from holders of 50.2% of outstanding shares authorizes 1,000,000 shares of blank check preferred stock, clearing the way for conversion of $21.1M in May 2026 convertible notes into Series A Preferred Stock. The filing reveals the full terms: a $1,000 stated value, 10% dividend accrual after six months, and a conversion price that resets to the lesser of $50.00 or the market price with a floor that drops to 20% of the closing price on the Mandatory Conversion Date. The company's own dilution tables show existing common stockholders could face up to 95.2% dilution at a $0.50 conversion price. This is a toxic financing structure — the lower the stock price falls, the more shares get issued, creating a death-spiral dynamic that could crush the stock. The filing also confirms the election of five directors and ratification of Suri & Co. as auditor, but the preferred stock authorization is the dominant event.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MEDS was trading at $0.99 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $2.9M. The 52-week trading range was $0.82 to $86.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MEDS - Latest Insights

MEDS
Nov 16, 2026, 8:42 AM EST
Filing Type: PRE 14C
Importance Score:
8
Price at Filing: $0.7001
Real-time Price: $0.630 info
Change: -$0.0701 (-10%) info
Market Cap: $3.661M info
MEDS
Nov 16, 2026, 6:01 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.710
Real-time Price: $0.630 info
Change: -$0.080 (-11%) info
Market Cap: $3.661M info
MEDS
Nov 13, 2026, 5:12 PM EST
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.7251
Real-time Price: $0.630 info
Change: -$0.0951 (-13%) info
Market Cap: $3.661M info
MEDS
Nov 13, 2026, 4:15 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.7499
Real-time Price: $0.630 info
Change: -$0.1199 (-16%) info
Market Cap: $3.661M info
MEDS
Nov 13, 2026, 10:20 AM EST
Source: ACCESS Newswire
Importance Score:
8
Price at Filing: $0.8795
Real-time Price: $0.630 info
Change: -$0.2495 (-28%) info
Market Cap: $3.661M info